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Abstract
Recent genomic research efforts in multiple myeloma have revealed clinically relevant molecular subgroups beyond
conventional cytogenetic classiﬁcations. Implementing these advances in clinical trial design and in routine patient
care requires a new generation of molecular diagnostic tools. Here, we present a custom capture next-generation
sequencing (NGS) panel designed to identify rearrangements involving the IGH locus, arm level, and focal copy
number aberrations, as well as frequently mutated genes in multiple myeloma in a single assay. We sequenced 154
patients with plasma cell disorders and performed a head-to-head comparison with the results from conventional
clinical assays, i.e., ﬂuorescent in situ hybridization (FISH) and single-nucleotide polymorphism (SNP) microarray. Our
custom capture NGS panel had high sensitivity (>99%) and speciﬁcity (>99%) for detection of IGH translocations and
relevant chromosomal gains and losses in multiple myeloma. In addition, the assay was able to capture novel genomic
markers associated with poor outcome such as bi-allelic events involving TP53. In summary, we show that a multiple
myeloma designed custom capture NGS panel can detect IGH translocations and CNAs with very high concordance in
relation to FISH and SNP microarrays and importantly captures the most relevant and recurrent somatic mutations in
multiple myeloma rendering this approach highly suitable for clinical application in the modern era.
Introduction
Multiple myeloma is a heterogeneous disease in terms
of genomic alterations, clinical presentation, and survival
outcomes. The genetic landscape in multiple myeloma is
complex and historically includes two main categories of
abnormalities: hyperdiploidy, deﬁned as gains of odd
numbered chromosomes, and immunoglobulin heavy
chain (IGH) translocations, including t(4;14), t(6;14),
t(11;14), t(14;16), and t(14;20)1–3. In addition, recurrent
chromosomal gains and losses have been reported, e.g.
gain 1q, del(13q), and del(17p)2,3. Some of these aberra-
tions deﬁne subgroups of patients associated with poor
prognosis in the majority of published studies, e.g. t(4;14),
t(14;16), and del(17p)1,4.
The advent of next-generation sequencing (NGS) has
progressively expanded our knowledge of multiple
myeloma biology identifying new and recurrent driver
events such as single-nucleotide variants (SNVs) and
focal deletions5–9. Emerging data suggest that the cur-
rent high-risk deﬁnition can be further improved by
integration of recurrent mutations and distinct cytoge-
netic proﬁles with the International Staging System10–14.
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Speciﬁcally, bi-allelic events including TP53 and more
than three copies of 1q have been recently associated
with poor outcomes5,8,15.
Currently, in the standard of care setting, conventional
chromosome analysis, multiple myeloma targeted ﬂuor-
escence in situ hybridization (FISH) panels, and single-
nucleotide polymorphism (SNP) microarrays are used to
detect chromosome translocations and gains and losses in
multiple myeloma2,3. Conventional chromosome analysis
is labor intensive, has low genomic resolution, and is often
inadequate due to low mitotic activity and low percentage
of plasma cells in bone marrows16. Although FISH is
accurate to deﬁne distinct recurrent aberrations, it is
limited to the targets of the selected probes not allowing a
comprehensive cytogenetic characterization. SNP micro-
arrays have been used to summarize copy number chan-
ges in multiple myeloma. This approach still relies on
FISH for the detection of IGH translocations and usually
requires about 15–20% or more aberrant plasma cell
inﬁltration of the bone marrow which in turn limits the
availability to do parallel comprehensive genomic analysis
including V(D)J proﬁling for minimal residual disease
characterization/tracking17,18. Furthermore, neither FISH
nor SNP microarray approaches are able to capture
somatic point mutations.
We were motivated to develop a new targeted NGS
assay designed to capture frequently deﬁned multiple
myeloma subtypes. Speciﬁcally, the assay captures recur-
rent IGH translocations, arm level, and focal copy number
alterations (CNAs), as well as frequently mutated genes in
multiple myeloma ur aim was to develop a novel strategy
that could replace current standard of care assays and to
capture mutational status in multiple myeloma in a single
assay. In a head-to-head comparison with standard of care
FISH and SNP microarrays, our assay revealed an extre-
mely high concordance (sensitivity > 99% and speciﬁcity
> 99%) for both IGH translocations and CNAs. Addi-
tionally, we captured mutations and bi-allelic events
relevant to clinical outcomes in multiple myeloma. Our
study provides strong evidence that multiple myeloma
designed custom capture NGS panels are of directly
clinical relevance and can be used as a novel strategy to
replace the current standard of care techniques.
Methods
Custom capture next-generation sequencing panel
In this head-to-head comparison of standard of care
multiple myeloma genomic sub-typing assays (i.e. FISH
and SNP microarrays) and NGS-based genomic sub-typ-
ing, we used an in-house developed multiplex custom
capture NGS assay (named “myTYPE”) which has been
designed to detect the most common and relevant
genomic aberrations in multiple myeloma5–9,19,20. To
capture IGH (14q32) rearrangements, we included the
canonical IGH locus. CNAs are assessed through genome-
wide representation of SNPs, one in every 3Mb, to enable
detection of CNAs. To capture focal events, SNPs were
tiled at a higher density in loci and genes which are
commonly deleted or ampliﬁed in multiple myeloma3.
Additionally, we included 120 genes that were selected on
the basis of (a) genes frequently mutated in multiple
myeloma from earlier reports5–7,21–26, (b) genes that are
involved in important signaling pathways in multiple
myeloma, e.g. the MAPK and NFKB pathways (Supple-
mentary Table)6, (c) treatment targets and candidate
genes for drug resistance in multiple myeloma (e.g.,
CRBN, IKZF1, and IKZF3)27, and (d) candidate genes and
SNPs associated with an increased susceptibility of
developing multiple myeloma28. The total target space
was 2.06Mb. The ﬁnal bait design was created using
Nimblegen SeqCap.
Patient cohort
We identiﬁed 154 patients with plasma cell disorders
who presented to Memorial Sloan Kettering Cancer
Center (MSKCC) between 2015 and 2018 and had sam-
ples collected for conventional cytogenetic evaluation as
well as samples collected under the MSKCC’s institutional
tissue acquisition protocol. The bone marrow aspirate
specimens underwent CD138-positive enrichment
through magnetic bead sorting and were divided for FISH
and SNP microarray testing. DNA was extracted using
commercial Qiagen DNA extraction kits and used for
SNP microarray and sequencing with the custom capture
NGS panel. In addition, 16 unmatched bone normal
marrow samples from healthy donors were used as assay
controls to ﬁlter sequencing and chemistry speciﬁc arti-
facts and germline variation. All patients had consented to
MSKCC’s institutional tissue acquisition protocol and the
study was approved by the MSKCC Institutional
Review Board.
FISH and SNP microarray
FISH panels for multiple myeloma included probes for
t(4;14), t(6;14), t(8;14), t(11;14), t(14;16), and t(14;20) from
Abbott Molecular, Des Plaines, IL and Metasystems,
Newton, MA. All FISH testing was performed in the
MSKCCs clinical Cytogenetics Laboratory. Between 100
and 500 cells, if available, were analyzed. FISH probes for
translocations t(4;14) and t(11;14) were tested in all
patients while in six patients, there was not enough cell
material to test for t(6;14), t(8;14), t(14;16), and t(14;20).
SNP microarrays with 2.67 million probes including 750
thousand common and rare SNP probes (Cytoscan,
Affymetrix, Santa Clara, CA) were performed following
manufacturers protocol. Data analysis was performed
using Affymetrix ChAS 3 software and ASCAT29. Copy
neutral loss of heterozygosity (CN-LOH) was reported if
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the size was at least 10Mb at a terminal region or 20Mb
for an interstitial CN-LOH. For CNA comparison in this
study, only commonly recurrent multiple myeloma aber-
rations: del(1p), gain 1q, del(6q), del(8p), del(13q), del(14q),
del(16q), del(17p), and hyperdiploidy, were evaluated.
Custom capture NGS panel data generation and
processing
After DNA extraction, barcoded sequence libraries
(New England Biolabs, Kapa Biosystems, Wilmington,
MA, USA) were subjected to capture by hybridization
(Nimblegen SeqCap, Madison, WI, USA). Between 100
and 200 ng of gDNA was used as input for library con-
struction. DNA was subsequently sequenced on an Illu-
mina HiSeq 2500 sequencer to generate paired-end 101-
bp reads.
Translocations were analyzed using the algorithms
BRASS and Delly30,31. CNVKit and FACETS were used to
identify somatic CNAs32,33. Together with results from
CNVKit, B-Allele frequencies using SNPs from the 1000
genomes project were used to identify regions of CN-
LOH. The 16 unmatched control samples were com-
bined into a pooled reference for CNA comparison.
SNVs and indels were called combing results from
CaVEMan, Strelka2, Mutect2, and Pindel34–37. Bi-allelic
inactivation was assessed in patients with multiple mye-
loma and was deﬁned as having a CNA, e.g. arm level or
focal deletion, and somatic mutation affecting the same
gene. Tumor-speciﬁc IGH-V(D)J rearrangement
sequences were identiﬁed using the MiXCR algo-
rithm38,39. Detailed information on variant calling is
given in the Supplementary Material.
Results
Patient cohort
Bone marrow aspirates from 154 patients with plasma
cell disorders; multiple myeloma (N= 118), smoldering
multiple myeloma (N= 17), monoclonal gammopathy of
undetermined signiﬁcance) (N= 5), plasma cell leukemia
(N= 1), and light-chain (AL) amyloidosis (N= 13) were
included in the study (Table 1). With our custom capture
NGS assay (myTYPE), IGH translocations were detected
in 51%, multiple myeloma relevant CNAs in 83%, and
somatic mutations in 85% percent of patients (Fig. 1).
Assay coverage and sample purity
Sequencing using the custom capture NGS assay gen-
erated a median of 38 million paired-end reads per sample
resulting in a median target coverage of 651x per sample
(Supplementary Fig. S1). The coverage across the IGH
locus, exonic regions, genome-wide copy number SNPs,
and ﬁnger printing SNPs were homogeneous (Supple-
mentary Fig. S2).
The sample purity for SNP microarray was estimated
using ASCAT and for the custom capture NGS assay
using algorithms based on mutation calls. Median purity
was 75% using ASCAT. There was a high concordance
between the sample purity for the two methods (Pearson’s
r2= 0.61) (Fig. 2).
Comparison myeloma targeted FISH versus the custom
capture NGS assay
Across the 154 samples that were assessed with multiple
myeloma targeted FISH and our custom capture NGS
assay, 78 IGH translocations were detected by both
approaches with a 100% concordance for t(4;14), t(6;14),
t(11;14), t(14;16), and (14;20) (Table 2). One patient had
both t(11;14) and t(8;14) translocation detected using the
custom capture NGS assay, only the t(11;14) translocation
was detected with FISH in this sample (Supplementary
Fig. S3). In two patients, t(8;14) detected by FISH was not
conﬁrmed by our custom capture NGS assay. This may be
indicative of variable IGH breakpoints in MYC translo-
cations, which may be outside of the custom capture NGS
assay’s primer coverage (Supplementary Fig. S4). The
concordance was 96% (N= 75) with a sensitivity and
speciﬁcity of 97% and 100%, respectively, for the custom
capture NGS assay using FISH as the reference. The
distribution and concordance of each of the translocations
in the study cohort is given in Table 2 and Figs. 3 and 4.
Comparison of SNP microarray versus the custom capture
NGS assay
Focusing on the CNAs of relevance for multiple mye-
loma: del(1p), gain 1q, del(6q), del(8p), del(13q), del(14q),
del(16q), del(17p), and hyperdiploidy (HRD), there were
384 CNAs identiﬁed by both assays, 3 uniquely identiﬁed
by SNP microarray and 15 uniquely identiﬁed by the
custom capture NGS assay (Figs. 2 and 3). HRD, deﬁned
as extra copies of two or more of the odd chromosomes,
was detected in 73 patients with 100% concordance
Table 1 Patients’ characteristics.
Total, N (%) 154 (100%)
Median age, years (range) 63 (35–85)
Male sex, N (%) 76 (49%)
Diagnosis
Multiple myeloma, N (%) 118 (76%)
Smoldering multiple myeloma, N (%) 17 (11%)
Monoclonal gammopathy of undetermined
signiﬁcance, N (%)
5 (3%)
Plasma cell leukemia, N (%) 1 (1%)
AL amyloidosis, N (%) 13 (8%)
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Fig. 1 a IGH translocations, copy number alterations, and somatic mutations captured with myTYPE targeted sequencing. b Number of events in
relation to disease status.
Fig. 2 a Sample purity estimates SNP microarray and b correlation between sample purity estimated by SNP microarray and myTYPE sequencing.
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between SNP microarray and our custom capture NGS
assay. Del(13q) was the most frequent CNA (50%), fol-
lowed by gain 1q (36%) (Table 2). Del(17p) was found in
26 patients (17%) by both SNP microarray and the custom
capture NGS assay while two additional arm-level 17p
deletions were detected uniquely by the NGS assay.
The overall sensitivity and speciﬁcity were 99% and 99%,
respectively, for our custom capture NGS assay using SNP
microarray as reference. Copy neutral LOH was detected
using both SNP microarrays and the custom capture NGS
assay (CNAs and copy neutral LOH are shown in Sup-
plementary Figs. S5–S7). In addition, of the 55 cases
where a 1q gain was identiﬁed, more than one extra copy
of 1q was detected in eight cases (Supplementary Fig. S8).
There was no correlation between sample purity and
detection of genomic events in this study, similar to what
was observed in CoMMpass and previous whole-genome
sequencing studies40,41. There were no samples that did
not harbor any genomic aberrations; the less common
aberrations are speciﬁed in the Supplementary Material.
Mutations, small insertions, and deletions by the custom
capture NGS assay
At least one non-synonymous mutation was identiﬁed
in 132 of 154 (85%) samples. In these 132 samples, a total
of 362 non-synonymous SNVs and 51 Indels were
detected by our custom capture NGS assay (median 3/
sample). We found that 19% and 18% of the samples each
harbored KRAS and NRAS mutations, respectively, and
5% of patients harbored a BRAF V600E mutation. TP53,
FAM46C, and DIS3 were detected in 12%, 8%, and 6% of
patients, respectively (Fig. 1, Supplementary Figs. S9 and
S10). Moreover, we identiﬁed a tumor-speciﬁc clonal V
(D)J rearrangement sequence in 127 of 154 samples (82%).
With the availability of arm level and focal CNA
assessment and mutational data using our custom capture
NGS assay, we identiﬁed 20 patients with bi-allelic events
affecting TP53, FAM46C, RB1, and TRAF3 (Fig. 5). Spe-
ciﬁcally, among patients with a 17p deletion (N= 29), 13
patients (45%) had mutation of the non-deleted allele
causing bi-allelic inactivation of TP53 (Fig. 5).
Discussion
This is the ﬁrst large-scale head-to-head comparison of
standard of care targeted FISH panel and SNP microarray
versus a multiple myeloma designed custom capture NGS
assay designed to replace current standard of care prog-
nostic bone marrow assays for multiple myeloma patients
with a single test. The study is based on bone marrow
specimens from a well-deﬁned cohort of 154 patients with
Table 2 Common genomic aberrations and their detection rates using the custom capture next-generation sequencing
(NGS) assay and ﬂuorescent in situ hybridization (FISH) and single-nucleotide polymorphism (SNP) microarray,
respectively.
Aberration FISH/SNP microarray
and NGS assay
FISH/SNP microarray Unique NGS assay Unique Sensitivity, % (95% CI*) Speciﬁcity, % (95% CI*)
Overall 483 6 15 0.99 (0.97–1) 0.99 (0.99–1)
Del(1p) 28 1 0 0.97 (0.82–1) 1 (0.97–1)
Gain(1q) 55 1 0 0.98 (0.9–1) 1 (0.96–1)
Del(6q) 35 1 2 0.97 (0.85–1) 0.98 (0.94–1)
Del(8p) 33 0 2 1 (0.89–1) 0.98 (0.94–1)
Del(13q) 77 1 0 0.99 (0.93–1) 1 (0.95–1)
Del(14q) 40 0 5 1 (0.91–1) 0.96 (0.9–0.99)
Del(16q) 42 0 3 1 (0.92–1) 0.97 (0.93–0.99)
Del(17p) 26 0 2 1 (0.87–1) 0.98 (0.95–1)
HRD 73 0 0 1 (0.95–1) 1 (0.96–1)
t(4;14) 13 0 0 1 (0.75–1) 1 (0.97–1)
t(6;14) 1 0 0 1 (0.03–1) 1 (0.98–1)
t(8;14) 8 2 1 0.8 (0.44–0.97) 0.99 (0.96–1)
t(11;14) 48 0 0 1 (0.93–1) 1 (0.97–1)
t(14;16) 2 0 0 1 (0.16–1) 1 (0.98–1)
t(14;20) 2 0 0 1 (0.16–1) 1 (0.98–1)
FISH ﬂuorescent in situ hybridization, SNP single-nucleotide polymorphism, NGS next-generation sequencing, CI conﬁdence interval, HRD hyperdiploidy
Yellapantula et al. Blood Cancer Journal (2019)9:101 Page 5 of 9
Blood Cancer Journal
plasma cell disorders. Overall, we found an extremely high
concordance (sensitivity > 99% and speciﬁcity > 99%)
between our custom capture NGS assay and conventional
multiple myeloma targeted FISH/SNP microarrays for
detection of IGH translocations and CNAs. In addition to
proﬁling of IGH translocations and CNAs, our custom
capture NGS assay captures relevant somatic mutations in
multiple myeloma as well as bi-allelic inactivations that
are critically relevant for prognostic assessment. Our
ﬁndings are of high clinical importance as they support the
Fig. 3 Concordance and discordance for the detection of genomic aberrations: multiple myeloma targeted FISH and SNP microarray versus myTYPE.
Fig. 4 Comparison of multiple myeloma targeted FISH and SNP microarray versus myTYPE.
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use of one single assay that can replace current standard of
care bone marrow assays for multiple myeloma.
For any new assay that is introduced in clinical practice,
it should have higher sensitivity and speciﬁcity or be
more efﬁcient than current options. Multiple myeloma
targeted FISH and SNP microarray are labor intensive,
require relatively large amounts of bone marrow material,
and have limited sensitivity. In this head-to-head com-
parison, our custom capture NGS assay had a very high
sensitivity and speciﬁcity in comparison with FISH and
SNP microarray in capturing the recurrent genomic
aberrations in multiple myeloma. The concordance for
the common IGH translocations and HRD was 100%. The
only translocation that was not fully captured using the
custom capture NGS assay was t(8;14) likely due variable
IGH breakpoints inMYC translocations which may partly
be outside of the NGS assay primer coverage42. Regarding
CNAs, our custom capture NGS assay identiﬁed a
number of additional alterations not detected through
SNP microarray analyses.
As for capturing somatic mutations, available NGS
panels, such as MSK-IMPACT and FoundationOne CDx,
have proven their utility in identifying mutations and
CNAs43,44. However, none of these NGS panels have been
designed to capture IGH translocations relevant to mul-
tiple myeloma. Because approximately 50% of all patients
with multiple myeloma have IGH translocations, multiple
myeloma targeted FISH and SNP microarrays are still
required in parallel with these NGS panels43,44. Going
forward, it seems logical to conjecture that other groups
with interest and expertise in genomics and bioinfor-
matics will develop multiple myeloma designed custom
capture NGS assays for clinical use in the future. Also, as
new scientiﬁc insights become available, there will be
need for updated versions of existing multiple myeloma
designed custom capture NGS assays.
Analysis of somatic mutations in multiple myeloma is
becoming increasingly important for better prognostic
assessments and to identify actionable mutations for
targeted therapy. In the current analysis, we found that
the prevalence of KRAS and NRAS as well as the overall
landscape of somatic mutations were in line with the
published literature5–7. We conclude that our custom
capture NGS assay precisely captures comprehensive
genomic abnormalities beyond FISH and SNP micro-
arrays and shows that it is possible to replace current
standard of care prognostic bone marrow assays for
multiple myeloma patients with a single test.
Fig. 5 a Distribution of somatic mutations in selected tumor suppressor genes. b Bi-allelic events detected through sequencing with myTYPE.
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High-risk multiple myeloma is a relative terminology
that is subject to change as modern effective therapies are
constantly being improved10–12. Per the International
Myeloma Working Group consensus criteria, IGH
translocations t(4;14), t(14;16), and 17p deletions are
deﬁned as high-risk multiple myeloma and 1q gains have
been included in earlier versions of high-risk deﬁni-
tions4,45. More recently, novel potential oncogenes and
tumor suppressor genes have been reported in multiple
myeloma, e.g. PTPN11, PRKD2, IDH1/2, HUWE1, and
UBR5 in addition to the known driver genes in multiple
myeloma, i.e. KRAS, NRAS, BRAF, TP53, FAM46C, DIS3,
and more8. Importantly, bi-allelic inactivation of tumor
suppressor genes, particularly TP53, have been linked to
a dismal outcome in multiple myeloma15. As illustrated
in this study, an advantage of our custom capture NGS
assay is the integrated capture of CNAs and mutations
co-occurring in the same genes, allowing for the assess-
ment of bi-allelic events involving different types of
aberrations. Indeed, in 29 multiple myeloma patients
with 17p deletions, our custom capture NGS assay
detected TP53 mutations in 13 patients (45%), resulting
in bi-allelic TP53 inactivation. There is an urgent need
for functional studies designed to better understand
underlying mechanisms of such cases, which, in turn will
allow development of more rational therapies for these
patients.
Strengths of this study are the head-to-head compar-
ison of a large patient cohort, and as shown consistently
throughout this study, there is high concordance between
conventional assays (multiple myeloma targeted FISH
panels and SNP microarrays) and our custom capture
NGS assay when it comes to detection of IGH translo-
cations and CNAs. Limitations include the lack of normal
samples for comparison of mutation calling and it
imposes challenges for detection of LOH as the inference
is based on tumor variant allele frequencies alone. Fur-
thermore, our custom capture NGS assay is designed to
capture the IGH locus where >95% of IGH translocations
occur which may have impacted the detection of t(8;14)
translocations in this study. Also, immunoglobulin light-
chain translocations, i.e. IGK and IGL, may be involved in
the pathogenesis in multiple myeloma, however, due to
the scarcity of knowledge on their impact, our custom
capture NGS assay was not designed to detect IGK and
IGL translocations. Future updated versions of our assay
will be revised/expanded in its capture based on biolo-
gical discoveries.
In conclusion, our multiple myeloma developed custom
capture NGS assay captures IGH translocations, CNAs,
and relevant somatic mutations and thus enables trans-
lation of information from recent large sequencing efforts
into clinical care. The large head-to-head comparison
between targeted FISH panels and SNP microarrays
versus our custom capture NGS assay revealed extremely
high concordance in regard to detection of relevant IGH
translocations and CNAs in multiple myeloma. The
ability to capture relevant somatic mutations as well as
recurrent IGH translocations and all CNAs with high
sensitivity and speciﬁcity in a single assay further sup-
ports the clinical strengths of multiple myeloma devel-
oped custom capture NGS assays as optimal for patient
care in the modern era.
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